Health, pharma & the biotechnology mission

From Vaccine Maitri to BioE3

India frames biotechnology as a strategic sector. The Department of Biotechnology (DBT), created in 1986 under the Ministry of Science and Technology, is the apex policy body, supported by its public-sector enterprise BIRAC (Biotechnology Industry Research Assistance Council, 2012), which de-risks startup innovation. The flagship vision is the BioE3 Policy (‘Biotechnology for Economy, Environment and Employment’), approved by the Union Cabinet on 24 August 2024. BioE3 targets high-performance biomanufacturing across six themes: bio-based chemicals and enzymes; functional foods and smart proteins; precision biotherapeutics; climate-resilient agriculture; carbon capture and utilisation; and marine and space biotechnology. It establishes Biomanufacturing and Bio-AI hubs and Biofoundries, and explicitly aims to expand India's bioeconomy, which the Economic Survey and DBT report grew from about USD 10 billion (2014) to over USD 150 billion (2024), with a target of USD 300 billion by 2030.

Mission COVID Suraksha and the platform legacy

India's vaccine capability is its global calling card. Covaxin (BBV152), an inactivated whole-virion vaccine, was developed by Bharat Biotech with the ICMR–National Institute of Virology, Pune, and received WHO Emergency Use Listing on 3 November 2021. Covishield was the Serum Institute of India's licensed manufacture of the Oxford–AstraZeneca adenoviral-vector vaccine. ZyCoV-D (Zydus Cadila), cleared by the DCGI in August 2021, was the world's first approved plasmid DNA vaccine and India's first needle-free (jet-injector) vaccine. CORBEVAX (Biological E) was a protein sub-unit vaccine. iNCOVACC became the world's first intranasal COVID vaccine to receive approval (2022). These were financed partly through Mission COVID Suraksha under the Atmanirbhar Bharat 3.0 package.

Regulators and the gene-therapy frontier

The drug regulator is the Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India (DCGI), operating under the Drugs and Cosmetics Act, 1940 and the New Drugs and Clinical Trials Rules, 2019. For genetically engineered organisms and products, the Genetic Engineering Appraisal Committee (GEAC) under the Ministry of Environment (per the 1989 Rules of the Environment Protection Act, 1986) is the apex approver. In October 2023 GEAC recommended environmental release of DMH-11, India's first transgenic (GM) mustard hybrid — a recurring Prelims hook. On the cutting edge, in October 2024 the CDSCO approved NexCAR19, India's first indigenously developed CAR-T cell therapy (developed by IIT Bombay, Tata Memorial Centre and ImmunoACT) for B-cell cancers, dramatically cheaper than imported equivalents. India is also advancing gene therapy for sickle cell disease, aligned with the National Sickle Cell Anaemia Elimination Mission (2023, target 2047).

Why this matters for the exam

Health, pharma and biotechnology sit at the intersection of GS Paper 3 (‘developments in science and technology’; ‘indigenisation and new technology’; ‘biotechnology and IPR issues’) and GS Paper 2 (health governance, schemes). In Prelims, the UPSC reliably tests: the type of vaccine technology (inactivated vs viral-vector vs DNA vs protein sub-unit — a classic match-the-pairs trap), the correct regulator for a given product (CDSCO/DCGI for drugs vs GEAC for GMOs vs FSSAI for food), and the parent ministry of an institution. PYQ patterns confirm this: the 2021 Prelims asked about mRNA vaccines; questions on monoclonal antibodies, gene editing (CRISPR-Cas9) and stem cells recur.

How it is tested and what to retain

For Mains, expect application-oriented prompts: ‘India aims to become a USD 300 billion bioeconomy — discuss the enablers and challenges,’ or critical evaluation of GM crops, biosafety, and the patent regime under Section 3(d) of the Patents Act, 1970 (the Novartis v. Union of India, 2013 evergreening judgment) and compulsory licensing (Natco v. Bayer, 2012). Link biotech to the One Health approach and antimicrobial resistance (AMR).

High-yield facts to memorise:

• BioE3 Policy: Cabinet approval 24 August 2024; six themes; bioeconomy target USD 300 bn by 2030.
• DBT (1986) and BIRAC (2012) — ministry: Science & Technology.
• ZyCoV-D = world's first DNA vaccine; iNCOVACC = first intranasal COVID vaccine.
• NexCAR19 (2024) = India's first indigenous CAR-T therapy.
• DMH-11 = first GM mustard; cleared by GEAC (2023).
• National Sickle Cell Anaemia Elimination Mission (2023), elimination target 2047.
• India is the ‘pharmacy of the world’: largest global supplier of generic medicines by volume and the largest supplier of vaccines (Serum Institute is the world's largest vaccine maker by volume).

Frame answers around Atmanirbhar Bharat in critical drugs: the Production Linked Incentive (PLI) schemes for Bulk Drugs/APIs and Medical Devices (2020) address India's import dependence on Chinese Active Pharmaceutical Ingredients (APIs) — a strategic-vulnerability angle examiners reward.